The SCGE Consortium is supported by the NIH Common Fund through cooperative agreements administered by the National Center for Advancing Translational Sciences, NIH Office of the Director, National Heart, Lung, and Blood Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Neurological Disorders and Stroke, National Institute of Allergy and Infectious Diseases, National Human Genome Research Institute, and National Institute of Biomedical Imaging and Bioengineering. The consortium is managed by a trans-NIH working group representing multiple NIH Institutes and Centers. For more information about the SCGE NIH Working Group and the Common Fund, please go here.
The Somatic Cell Genome Editing (SCGE) Consortium is an NIH Common Fund organization that aims to develop safe and effective methods to perform gene editing to treat genetic diseases in somatic cells. The SCGE consists of a collection of scientists all with specialized expertise in gene editing. The SCGE is categorized into five different initiatives each with a specific purpose: Biological Effects, Delivery Systems, Genome Editors, Animal Reporter & Testing Centers, and the Dissemination & Coordinating Center.
A somatic cell is any cell in the body except for reproductive cells, such as sperm, eggs, or cells that become sperm or eggs.
Gene editing is a type of technology that can be used to make small changes to the DNA sequence in particular cells of an individual. With this technology, scientists have the ability to develop treatments for genetic diseases that would otherwise be incurable.